Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1–related hepatocellular carcinoma in the Guangxi population

Authors

  • Xi-Dai Long,

    1. Department of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    2. Department of Pathology, Youjiang Medical College for Nationalities, Baise, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yun Ma,

    1. Department of Pathology, Guangxi Medical University, Nanning, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Yuan-Feng Zhou,

    1. Department of Pathology, Youjiang Medical College for Nationalities, Baise, China
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Ai-Min Ma,

    1. Department of Pathology, Youjiang Medical College for Nationalities, Baise, China
    Search for more papers by this author
  • Guo-Hui Fu

    Corresponding author
    1. Department of Pathology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    • Department of Pathology, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, China 200025
    Search for more papers by this author
    • 21 63846590 (776601)


  • Potential conflict of interest: Nothing to report.

Abstract

Genetic polymorphisms in DNA repair genes may influence individual variations in DNA repair capacity, and this may be associated with the risk and outcome of hepatocellular carcinoma (HCC) related to aflatoxin B1 (AFB1) exposure. In this study, we focused on the polymorphism of xeroderma pigmentosum complementation group C (XPC) codon 939 (rs#2228001), which is involved in nucleotide excision repair. We conducted a case-control study including 1156 HCC cases and 1402 controls without any evidence of hepatic disease to evaluate the associations between this polymorphism and HCC risk and prognosis in the Guangxi population. AFB1 DNA adduct levels, XPC genotypes, and XPC protein levels were tested with a comparative enzyme-linked immunosorbent assay, TaqMan polymerase chain reaction for XPC genotypes, and immunohistochemistry, respectively. Higher AFB1 exposure was observed among HCC patients versus the control group [odds ratio (OR) = 9.88 for AFB1 exposure years and OR = 6.58 for AFB1 exposure levels]. The XPC codon 939 Gln alleles significantly increased HCC risk [OR = 1.25 (95% confidence interval = 1.03-1.52) for heterozygotes of the XPC codon 939 Lys and Gln alleles (XPC-LG) and OR = 1.81 (95% confidence interval = 1.36-2.40) for homozygotes of the XPC codon 939 Gln alleles (XPC-GG)]. Significant interactive effects between genotypes and AFB1 exposure status were also observed in the joint-effects analysis. This polymorphism, moreover, was correlated with XPC expression levels in cancerous tissues (r = −0.369, P < 0.001) and with the overall survival of HCC patients (the median survival times were 30, 25, and 19 months for patients with homozygotes of the XPC codon 939 Lys alleles, XPC-LG, and XPC-GG, respectively), especially under high AFB1 exposure conditions. Like AFB1 exposure, the XPC codon 939 polymorphism was an independent prognostic factor influencing the survival of HCC. Additionally, this polymorphism multiplicatively interacted with the xeroderma pigmentosum complementation group D codon 751 polymorphism with respect to HCC risk (ORinteraction = 1.71). Conclusion: These results suggest that the XPC codon 939 polymorphism may be associated with the risk and outcome of AFB1-related HCC in the Guangxi population and may interact with AFB1 exposure in the process of HCC induction by AFB1. (HEPATOLOGY 2010;)

Ancillary